Topiramate extended-release capsules (USL255) up to a maximum of 400 mg per day

Drug: USL255

Other Name: Topiramate extended-release

Eligibility

Ages Eligible for Study:

18 Years to 75 Years

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Have completed the maintenance period of the P09-004 study.

Continue to be treated with a stable dose of 1 to a maximum of 3 approved concomitant AEDs.

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01191086